Clinical Trial Detail

NCT ID NCT03343197
Title Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

astrocytoma

oligodendroglioma

Therapies

Ivosidenib

AG-881

Age Groups: adult senior

Additional content available in CKB BOOST